Why MannKind Corporation (MNKD) Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, biopharmaceutical company MannKind Corporation (NASDAQ:MNKD) has received a distressing two-star ranking.

MannKind Corporation (NASDAQ:MNKD)

With that in mind, let’s take a closer look at MannKind Corporation (NASDAQ:MNKD) and see what CAPS investors are saying about the stock right now.

MannKind

Headquarters (founded)

Valencia, Calif. (1991)

Market Cap

$2.1 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$35 thousand

Management

Founder/Chairman/CEO Alfred Mann

President/COO Hakan Edstrom

Return on Equity (average, past 3 years)

(39.4%)

Cash/Debt

$28.0 million / $332.0 million

Competitors

Eli Lilly (NYSE:LLY)
GlaxoSmithKline (NYSE:GSK)
Novo (NYSE:NVO) Nordisk

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 16% of the 695 members who have rated MannKind Corporation (NASDAQ:MNKD) believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, tapped the stock’s recent surge as particularly unsustainable:

At the end of last year I looked over all the stocks in my biopharma database and tried to predict which would be the biggest runner of 2013. My conclusion? MannKind Corporation (NASDAQ:MNKD). But I never bought in or even green thumbed because the run started earlier than I expected and I kept waiting for a pullback that never came. … And after the company solidified their guidance to topline results of Affinity 1 and Affinity 2 in mid August, the stock went parabolic. The moral: don’t be so obsessed with catching a stock at the absolute bottom. …

Now I’m left with another crummy red thumb. I don’t think MannKind Corporation (NASDAQ:MNKD) is worth two billion even if the Affinity trials are a resounding success and Afrezza is approved the next time round. I’ve been a long-term bear on MannKind for years and my reasons are well-documented here. A 300% rise in share price this year is completely unjustified and simply represents traders playing the “greater fool” game. I’m terrible at judging when that game will end but at some inflection point, whether it is positive data or drug approval, this stub is going to tank.

The article Why MannKind Is Poised to Pull Back originally appeared on Fool.com and is written by Brian Pacampara.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!